PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022

NEW YORK, April 10, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01158411/PharmaPoint-Osteoporosis---US-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

The large dip in sales caused by these expiries is offset by six pipeline product launches over the forecast period, with three of these being potential blockbuster drugs. This next generation of drugs typically consists of biologics and will be higher priced than the drugs losing patent protection in the first half of the forecast period.

Scope

- Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Osteoporosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Risk Factors 17
3.1.4 Quality of Life 17
3.2 Symptoms 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Diagnosis and Referral 19
4.1.2 Treatment Guidelines 20
4.1.3 Disease Management 22
4.2 United States 25
4.2.1 Diagnosis 25
4.2.2 Clinical Practice 26
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 27
5.3 Product Profiles – Major Brands 31
5.3.1 Actonel (risedronate sodium) 31
5.3.2 Evista (raloxifene hydrochloride) 34
5.3.3 Reclast (zolendronic acid) 37
5.3.4 Forteo (teriparatide) 40
5.3.5 Prolia (denosumab) 44
5.3.6 Protelos (strontium ranelate) 47
5.3.7 Miacalcin and Fortical (calcitonin-salmon) 50
5.3.8 Viviant/Conbriza (bazedoxifene) 54
5.3.9 Recalbon/Bonoteo (minodronic acid hydrate) 57
5.3.10 Alendronate sodium 60
5.3.11 Ibandronate 61
6 Opportunity and Unmet Need 63
6.1 Overview 63
6.2 Unmet Needs 64
6.2.1 Disease Awareness and Early Diagnosis 64
6.2.2 Patient Compliance 65
6.2.3 Efficacy 66
6.2.4 Safety 67
6.2.5 Treatment Cost 67
6.2.6 Earlier Intervention 68
6.3 Unmet Needs Gap Analysis 69
6.4 Opportunity 1: Dual-Action Therapies 70
6.5 Opportunity 2: Osteoporosis Prevention Therapies 71
6.6 Opportunity 3: Dosing and Administration 72
7 Pipeline Assessment 73
7.1 Overview 73
7.2 Promising Drugs in Clinical Development 74
7.2.1 Aprela (bazedoxifene and conjugated estrogens) 76
7.2.2 Romosozumab (AMG-785) 82
7.2.3 Odanacatib 88
7.2.4 BA-058 94
7.2.5 PTH(1-31)NH2 99
7.2.6 Ostora (recombinant salmon calcitonin) 104
8 Market Outlook 109
8.1 United States 109
8.1.1 Forecast 109
8.1.2 Key Events 112
8.1.3 Drivers and Barriers 112
9 Appendix 115
9.1 Bibliography 115
9.2 Abbreviations 122
9.3 Methodology 125
9.4 Forecasting Methodology 125
9.4.1 Diagnosed Osteoporosis Patients 125
9.4.2 Percent Drug-Treated Patients 125
9.4.3 Drugs Included in Each Therapeutic Class 126
9.4.4 Launch and Patent Expiry Dates 126
9.4.5 General Pricing Assumptions 127
9.4.6 Individual Drug Assumptions 127
9.4.7 Generic Erosion 132
9.4.8 Pricing of Pipeline Agents 132
9.5 Physicians and Specialists Included in this Study 133
9.5.1 About the Authors 134
9.5.2 Global Head of Healthcare 135
9.6 About GlobalData 136
9.7 Contact Us 136
9.8 Disclaimer 136

List of Tables

Table 1: Etiology of Primary Osteoporosis 13
Table 2: Etiology of Secondary Osteoporosis 15
Table 3: Symptoms of Osteoporosis 18
Table 4: Diagnostic Tests for Osteoporosis 19
Table 5: T-Score Ranges for Determination of BMD 20
Table 6: Treatment Guidelines for Osteoporosis 21
Table 7: Most Prescribed Drugs for Osteoporosis by Therapeutic Class in the Global Markets, 2012 23
Table 8: Leading Treatments for Osteoporosis, 2012 30
Table 9: Product Profile – Actonel 32
Table 10: Actonel SWOT Analysis, 2012 33
Table 11: Product Profile – Evista 35
Table 12: Evista SWOT Analysis, 2012 36
Table 13: Product Profile – Reclast 38
Table 14: Reclast SWOT Analysis, 2012 39
Table 15: Product Profile – Forteo 41
Table 16: Mean Percent Change from Baseline in BMD with Forteo vs. Placebo in Postmenopausal Women with Osteoporosis 42
Table 17: Forteo SWOT Analysis, 2012 43
Table 18: Product Profile – Prolia 44
Table 19: Prolia SWOT Analysis, 2012 46
Table 20: Product Profile – Protelos 47
Table 21: Protelos SWOT Analysis, 2012 48
Table 22: Product Profile – Miacalcin and Fortical Nasal Spray 51
Table 23: Adverse Events with Miacalcin Nasal Spray 51
Table 24: Miacalcin and Fortical Nasal Spray SWOT Analysis, 2012 52
Table 25: Product Profile – Viviant/Conbriza 54
Table 26: Viviant/Conbriza SWOT Analysis, 2012 56
Table 27: Product Profile – Recalbon/Bonoteo 57
Table 28: Recalbon/Bonoteo SWOT Analysis, 2012 58
Table 29: Overall Unmet Needs – Current Level of Attainment 63
Table 30: Clinical Unmet Needs – Gap Analysis, 2012 69
Table 31: Osteoporosis – Pipeline, 2012 74
Table 32: Comparison of Therapeutic Classes in Development for Osteoporosis, 2012 74
Table 33: Product Profile – Aprela 77
Table 34: Aprela SWOT Analysis, 2012 80
Table 35: Product Profile – Romosozumab 82
Table 36: Romosozumab SWOT Analysis, 2012 86
Table 37: Product Profile – Odanacatib 88
Table 38: Odanacatib SWOT Analysis, 2012 92
Table 39: Product Profile – BA-058 94
Table 40: BA-058 SWOT Analysis, 2012 97
Table 41: Product Profile – PTH(1-31)NH2 99
Table 42: PTH(1-31)NH2 SWOT Analysis, 2012 102
Table 43: Product Profile – Ostora 105
Table 44: Ostora SWOT Analysis, 2012 107
Table 45: US Sales Forecasts ($m) for Osteoporosis, 2012-2022 110
Table 46: Key Events Impacting Sales for Osteoporosis in the US, 2012–2022 112
Table 47: Osteoporosis Market – Drivers and Barriers in the United States, 2012–2022 112
Table 48: Key Launch Dates 126
Table 49: Key Patent Expiries 126
Table 50: Number of High-Prescribing Physicians Surveyed 133

List of Figures

Figure 1: Company Portfolio Gap Analysis in Osteoporosis, 2012–2022 75
Figure 2: Sales for Osteoporosis Drugs in the United States by Drug Class, 2012–2022 111

To order this report:
Drug_and_Medication Industry: PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker